ReviewHeart failure reviews2013
Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.
Review in Heart failure reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Intravenous immunoglobulin for presumed viral myocarditis in children and adults.The Cochrane database of systematic reviews · 2020Pooled it
- Myocarditis with neurological and dermatological involvement in idiopathic Hypereosinophilic syndrome: Case report.Radiology case reports · 2025Article
- Eosinophilic Myocarditis: From Bench to Bedside.Biomedicines · 2024Review
- Interferons and interferon-related pathways in heart disease.Frontiers in cardiovascular medicine · 2024Review
- Development of Antiarrhythmic Therapy-Resistant Ventricular Tachycardia, Ventricular Fibrillation, and Premature Ventricular Contractions in a 15-Year-Old Patient.Journal of pediatric intensive care · 2022Article
- Differences in Prognosis and Cardiac Function According to Required Percutaneous Mechanical Circulatory Support and Histological Findings in Patients With Fulminant Myocarditis: Insights From the CHANGE PUMP 2 Study.Journal of the American Heart Association · 2022Article
- Research focus and theme trend on fulminant myocarditis: A bibliometric analysis.Frontiers in cardiovascular medicine · 2022Article
- Study on the Changes and Significance of Immune State and Cycokines in Children with Adenovirus Pneumonia.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Eosinophilic Myocarditis in a Patient WithJACC. Case reports · 2021Article
- Article
- Review
- CCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5.Journal of translational medicine · 2018Article
- Treatment options in myocarditis and inflammatory cardiomyopathy : Focus on i. v. immunoglobulins.Herz · 2018Review
- Diagnosis, medical treatment, and stepwise mechanical circulatory support for fulminat myocarditis.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2018Article
- Review
- The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart.Journal of immunology research · 2016Review
- Article
- Article
- Mapping myocarditis: still searching for the north star.JACC. Cardiovascular imaging · 2014Article
- Management of fulminant myocarditis: a diagnosis in search of its etiology but with therapeutic options.Current heart failure reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In inflammatory dilated cardiomyopathy and myocarditis, there is apart from heart failure and antiarrhythmic therapies no alternative to an etiologically driven specific treatment. Their prerequisites are noninvasive and invasive biomarkers including endomyocardial biopsy and PCR on cardiotropic agents. This review deals with the different etiologies of myocarditis and inflammatory cardiomyopathy including the genetic background, the predisposition for heart failure and inflammation. It analyses the epidemiologic shift in pathogenetic agents in the last 20 years, the role of innate and acquired immunity including the T cell and B cell driven immune responses. On this basis, it summarizes phases and clinical faces of myocarditis. It gives an up-to-date information on current treatment options starting with heart failure and antiarrhythmic therapy. Although inflammation can resolve spontaneously, often specific treatment directed to the causative etiology is required. For fulminant, acute and chronic autoreactive myocarditis immunosuppressive treatment is beneficial; for viral cardiomyopathy and myocarditis, IVIG can resolve inflammation and is as successful as interferon therapy in enteroviral and adenoviral myocarditis. Eradication of parvovirus B19 and HHV6 myocarditis is still a problem by anyone of these treatment options. The potential of stem cell therapy has to be tested in future trials. In perimyocardial disease, a locoregional approach with high local doses and low systemic side effects have been shown highly efficient by intrapericardial treatment of triamcinolonacetate facilitated by pericardioscopy for adequate etiopathogenetic diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.